<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="at: [[inbox]]
Rheumatology - Crystal-Induced Arthritis - Fast Facts | NEJM Resident 360 Crystal-induced arthritis is characterized by an acute arthritis of one or several joints; typical features include pain, swelling, erythema, heat, and restricted function."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Rheumatology - Crystal-Induced Arthritis - Fast Facts | NEJM Resident 360"><title>Rheumatology - Crystal-Induced Arthritis - Fast Facts | NEJM Resident 360</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.357a117d84ac53f7b6d803e28b8795df.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.be8b0ee8582f9c3295529c05bdd3bcd8.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Rheumatology - Crystal-Induced Arthritis - Fast Facts | NEJM Resident 360</h1><p class=meta>最後更新於
Feb 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Rheumatology%20-%20Crystal-Induced%20Arthritis%20-%20Fast%20Facts%20%20NEJM%20Resident%20360.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><p>at: <a href=/inbox rel=noopener class=internal-link data-src=/inbox>inbox</a></p><a href=#rheumatology---crystal-induced-arthritis---fast-facts--nejm-resident-360><h1 id=rheumatology---crystal-induced-arthritis---fast-facts--nejm-resident-360><span class=hanchor arialabel=Anchor># </span>Rheumatology - Crystal-Induced Arthritis - Fast Facts | NEJM Resident 360</h1></a><p>Crystal-induced arthritis is characterized by an acute arthritis of one or several joints; typical features include pain, swelling, erythema, heat, and restricted function. Fever and elevated markers of inflammation in peripheral blood are common findings, so infection is the main alternative in the differential diagnosis.</p><p>Ideally, every case of suspected crystal-induced arthritis is confirmed by arthrocentesis and synovial fluid analysis, with visualization of the relevant crystal and the absence of bacterial growth on culture media, although joint aspiration is not possible or positive in every case. There are two main types of crystal: monosodium urate (gout) and calcium pyrophosphate (pseudogout).</p><p>A third crystal type, basic calcium phosphate, is associated with osteoarthritis, calcific periarthritis, and, more rarely, severe joint destruction. It is not discussed further in this section.</p><p>In this section, we review the following conditions:</p><ul><li><p>Gout</p></li><li><p>Calcium Pyrophosphate Deposition (CPPD) Disease or Pseudogout</p></li></ul><a href=#gout><h2 id=gout><span class=hanchor arialabel=Anchor># </span>Gout</h2></a><p>Gout is a type of inflammatory arthritis that is caused by the deposition of monosodium urate crystals in synovial fluid and other tissues.</p><a href=#three-clinical-phases-of-gout><h3 id=three-clinical-phases-of-gout><span class=hanchor arialabel=Anchor># </span>Three Clinical Phases of Gout</h3></a><ul><li><p>acute gouty arthritis</p></li><li><p>intercritical period: patients are entirely asymptomatic during this phase</p></li><li><p>chronic gout: if hyperuricemia is not treated, chronic tophaceous gout may develop, characterized by polyarticular attacks, symptoms between attacks, and crystal deposition (tophi) in soft tissues or joints</p></li></ul><a href=#risk-factors><h3 id=risk-factors><span class=hanchor arialabel=Anchor># </span>Risk Factors</h3></a><ul><li><p>medications: thiazide and loop diuretics, cyclosporine, and low-dose aspirin (&lt;1 gram daily)</p></li><li><p>insulin resistance, metabolic syndrome, and obesity</p></li><li><p>chronic renal insufficiency</p></li><li><p>hypertension</p></li><li><p>congestive heart failure</p></li><li><p>organ transplantation</p></li><li><p>disorders of high cell turnover (e.g., hematologic malignancy)</p></li><li><p>high intake of dietary purines (particularly meat and seafood), ethanol (particularly beer and spirits), soft drinks, and other sources of high-fructose corn syrup</p></li></ul><a href=#triggers-of-gout-flares><h3 id=triggers-of-gout-flares><span class=hanchor arialabel=Anchor># </span>Triggers of Gout Flares</h3></a><ul><li><p>recent diuretic use</p></li><li><p>alcohol intake</p></li><li><p>hospitalization (particularly if dehydrated or admitted with sepsis)</p></li><li><p>surgery</p></li><li><p>urate-lowering therapy in the early period after its initiation (especially if treatment is not accompanied by therapy for flare prophylaxis, such as with colchicine)</p></li></ul><a href=#diagnosis><h3 id=diagnosis><span class=hanchor arialabel=Anchor># </span>Diagnosis</h3></a><p>The gold standard for diagnosis of gout is aspiration of synovial fluid or tophi aspiration with identification of negatively birefringent monosodium urate crystals under polarizing microscopy.</p><a href=#tophaceous-gout><h3 id=tophaceous-gout><span class=hanchor arialabel=Anchor># </span>Tophaceous Gout</h3></a><p><strong>Gouty tophi of the right index finger (panel A), osteolysis of the distal phalanx (panel B), and urate crystals on polarized light microscopy (panel C).<br>(Source: Tophaceous Gout. N Engl J Med 2012.)</strong></p><a href=#management><h3 id=management><span class=hanchor arialabel=Anchor># </span>Management</h3></a><p><strong>Acute gout attacks:</strong> The following table describes pharmacologic management options for acute gout attacks:</p><p><strong>(Source: Gout. N Engl J Med 2011.)</strong> </p><p>In circumstances where oral glucocorticoids are unsuitable (such as vomiting), intra-articular or intramuscular administration of glucocorticoids can be used as an alternative. In patients with resistant disease, investigational therapies to consider include anti-inflammatory agents that target interleukin-1, such as anakinra and canakinumab, though they increase the risk of infection.</p><p><strong>Chronic gout:</strong> Patients with tophi, frequent attacks (≥2 per year), polyarticular attacks, chronic kidney disease stage 2 or worse, or previous urolithiasis should be considered for urate-lowering therapy. This therapy can be started in conjunction with treatment for acute gout or can be delayed and started after an acute episode resolves.</p><ul><li><p><strong>Allopurinol</strong> is the first-line agent and should be started at a low dose (≤100 mg daily) and up-titrated every 3 to 5 weeks to reach a goal uric acid level of &lt;6 mg/dL. Underdosing of allopurinol is common.</p><ul><li><p>Treating to a uric acid target of &lt;6 mg/dL (or lower) will promote regression of tophi, reduce frequency of flares, and improve imaging-detected synovitis. See this review article for further details on treating gout to target.</p></li><li><p>Allopurinol is rarely associated with a life-threatening hypersensitivity reaction. This reaction is most likely to occur within the first 3 months of treatment, in those with renal insufficiency, and in genetically susceptible individuals. Patients with the <em>HLA-B</em>5801* allele (most commonly found in African Americans and people of Thai, Korean, and Han Chinese descent) are a susceptible group, and allopurinol use is contraindicated for patients with this genetic variant. Screening for this allele is recommended for individuals in these higher risk populations.</p></li><li><p>All patients started on allopurinol should receive gout prophylaxis with low-dose colchicine, low-dose nonsteroidal anti-inflammatory drugs (NSAIDs), or glucocorticoids. The choice of therapy is individualized to the patient and their concomitant medications and comorbidities.</p></li><li><p>Gout prophylaxis (using colchicine, NSAIDs, or glucocorticoids) should continue for at least 3 to 6 months after achieving the goal uric acid level if there are no additional flares.</p></li><li><p>Unless there is an adverse reaction, <strong>allopurinol should NOT be stopped</strong>, because stopping can provoke further flares. This applies to patients admitted for other conditions; if the patient is hemodynamically stable and tolerating their usual outpatient dose of allopurinol, it can be continued even in the setting of renal insufficiency.</p></li></ul></li><li><p><strong>Febuxostat</strong> is an alternative urate-lowering therapy and is generally reserved for when there is an allergy or intolerance to allopurinol. Concerns have been raised regarding an observed increase in cardiovascular events in clinical trials with febuxostat, and the FDA required a warning with this drug’s prescribing information.</p></li><li><p><strong>Probenecid</strong> promotes the excretion of uric acid in the urine. It is less potent than allopurinol or febuxostat, raises the risk of nephrolithiasis, and may be ineffective in the setting of renal dysfunction.</p></li><li><p><strong>Pegloticase</strong> is approved in the U.S. but rarely used. It is administered as an intravenous infusion every 2 weeks and often causes infusion reactions.</p></li></ul><a href=#calcium-pyrophosphate-deposition-cppd-disease-or-pseudogout><h2 id=calcium-pyrophosphate-deposition-cppd-disease-or-pseudogout><span class=hanchor arialabel=Anchor># </span>Calcium Pyrophosphate Deposition (CPPD) Disease or Pseudogout</h2></a><p>CPPD is a crystal-induced joint disease caused by the deposition of calcium pyrophosphate crystals into connective tissues. It manifests as a spectrum of conditions including asymptomatic chondrocalcinosis (which is incidentally found on radiographs), episodes of arthritis that mimic gout (pseudogout), rheumatoid arthritis (pseudo–rheumatoid arthritis), and accelerated osteoarthritis.</p><p>CPPD most often affects older patients who often have multiple comorbidities. The knee is the most commonly affected joint, followed by the wrist.</p><a href=#risk-factors-1><h3 id=risk-factors-1><span class=hanchor arialabel=Anchor># </span>Risk Factors</h3></a><p>Most cases are idiopathic, but risk factors include:</p><ul><li><p>hypercalcemia</p></li><li><p>hypomagnesemia</p></li><li><p>hypophosphatasia</p></li><li><p>hemochromatosis</p></li><li><p>trauma</p></li></ul><p>Secondary causes should be suspected in younger patients with CPPD. Screening for the conditions outlined above is recommended at least once in all patients with CPPD.</p><a href=#imaging><h3 id=imaging><span class=hanchor arialabel=Anchor># </span>Imaging</h3></a><p>Radiographs often demonstrate chondrocalcinosis. However, the absence of this radiographic finding does not rule out disease, and its presence is common in asymptomatic older individuals; therefore, chondrocalcinosis does not itself require treatment. Chondrocalcinosis typically develops in the cartilage of the knee joint, the triangular fibrocartilaginous complex of the wrist, the pubic symphysis, or any combination of these. </p><a href=#diagnosis-1><h3 id=diagnosis-1><span class=hanchor arialabel=Anchor># </span>Diagnosis</h3></a><p>Diagnosis usually requires arthrocentesis and synovial fluid analysis showing polymorphic rhomboid and rod-shaped crystals that exhibit weak positive birefringence.</p><a href=#calcium-pyrophosphate-deposition><h3 id=calcium-pyrophosphate-deposition><span class=hanchor arialabel=Anchor># </span>Calcium Pyrophosphate Deposition</h3></a><p><strong>Rhomboid, birefringent calcium pyrophosphate (CPP) crystals are seen under polarizing light microscopy in this sample of synovial fluid that was obtained from a patient with acute CPP crystal arthritis of the wrist (panel A). The hands of an elderly patient with CPPD disease show swelling in the left wrist and the third proximal interphalangeal joint of the left hand (panel B).<br>(Source: Calcium Pyrophosphate Deposition Disease. N Engl J Med 2016.</strong>)****</p><a href=#treatment-of-acute-cppd><h3 id=treatment-of-acute-cppd><span class=hanchor arialabel=Anchor># </span>Treatment of Acute CPPD</h3></a><p>Treatment of acute CCPD is similar to that of gout and can include:</p><ul><li><p>NSAIDs</p></li><li><p>colchicine</p></li><li><p>systemic or intra-articular glucocorticoids</p></li></ul><a href=#prevention><h3 id=prevention><span class=hanchor arialabel=Anchor># </span>Prevention</h3></a><p>Prevention of CPPD is challenging. If there are risk factors for CPPD, these should be addressed. However, no drugs prevent further CPPD. Colchicine, NSAIDs, or glucocorticoids are sometimes prescribed to prevent flares. Refractory disease may require treatment with hydroxychloroquine or methotrexate, though there is little evidence of benefit for these drugs and their use is generally not recommended. Interleukin-1 inhibitors, such as anakinra, are considered investigational for the treatment of CPPD.</p><p><a href=/inbox rel=noopener class=internal-link data-src=/inbox>inbox</a></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/all-list-of-resident360/ data-ctx="Rheumatology - Crystal-Induced Arthritis - Fast Facts  NEJM Resident 360" data-src=/all-list-of-resident360 class=internal-link>all list of resident360</a></li><li><a href=/rheumatology/ data-ctx="Rheumatology - Crystal-Induced Arthritis - Fast Facts  NEJM Resident 360" data-src=/rheumatology class=internal-link>rheumatology</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>